DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ceprotin (Protein C) - Summary

 
 



CEPROTIN SUMMARY

CEPROTIN [Protein C Concentrate (Human)] is manufactured from human plasma purified by a combination of filtration and chromatographic procedures, including a column of immobilized mouse monoclonal antibodies on gel beads. See WARNINGS/PRECAUTIONS: Transmission of Infectious Agents .

CEPROTIN is indicated for patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans. CEPROTIN is indicated as a replacement therapy for pediatric and adult patients.


See all Ceprotin indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Ceprotin (Protein C)

Protein called YAP gives blood vessels strength and shape
Source: Biology / Biochemistry News From Medical News Today [2014.03.26]
When yes-associated protein, or YAP, is deleted from vascular smooth muscle cells during development, the protein makes thin-walled blood vessels that over-dilate in response to the usual pressure...

Single protein controls Drosophila nervous system development and survival
Source: Schizophrenia News From Medical News Today [2014.03.03]
A protein that controls the metamorphosis of the common fruit fly could someday play a role in reversing brain injuries, said Duke University researchers.

Discovery Of Defective Regulatory Protein Could Increase Efficacy Of Promising Cystic Fibrosis Drug
Source: Cystic Fibrosis News From Medical News Today [2013.03.26]
A little more than a year after the FDA approved Kalydeco (Vx-770), the first drug of its kind to treat the underlying cause of cystic fibrosis, University of Missouri researchers believe they have...

Study 'Big Deal' for AML Patients (CME/CE)
Source: MedPage Today Oncology/Hematology [2014.04.08]
SAN DIEGO (MedPage Today) -- Six of seven patients with relapsed acute myeloid leukemia responded to treatment that targets a mutant protein closely associated with the disease, according to results of an early study reported here.

Major mechanism identified that drives kidney cancer progression
Source: Urology / Nephrology News From Medical News Today [2014.03.24]
The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP - which...

more news >>

Published Studies Related to Ceprotin (Protein C)

Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011.09]
Chronic wounds arising from orthopedic surgery present a major clinical challenge. Osteomyelitis may develop from polymicrobial infection, which can be unresponsive to treatment and lead to amputation...

A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. [2011.08]
OBJECTIVE: To investigate the association between markers of acute endothelial glycocalyx degradation, inflammation, coagulopathy, and mortality after trauma. BACKGROUND: Hyperinflammation and acute coagulopathy of trauma predict increased mortality. High catecholamine levels can directly damage the endothelium and may be associated with enhanced endothelial glycocalyx degradation, evidenced by high circulating syndecan-1... CONCLUSIONS: In trauma patients, high circulating syndecan-1, a marker of endothelial glycocalyx degradation, is associated with inflammation, coagulopathy and increased mortality.

Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. [2011.04.15]
RATIONALE: Patients with acute lung injury have impaired function of the lung surfactant system. Prior clinical trials have shown that treatment with exogenous recombinant surfactant protein C (rSP-C)-based surfactant results in improvement in blood oxygenation and have suggested that treatment of patients with severe direct lung injury may decrease mortality. OBJECTIVES: Determine the clinical benefit of administering an rSP-C-based synthetic surfactant to patients with severe direct lung injury due to pneumonia or aspiration... CONCLUSIONS: In this study, rSP-C-based surfactant was of no clinical benefit to patients with severe direct lung injury. The unexpected lack of improvement in oxygenation, coupled with the results of in vitro tests, suggest that the administered suspension may have had insufficient surface activity to achieve clinical benefit.

Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. [2011]
INTRODUCTION: There are no published data on the status of endogenous activated protein C (APC) in pulmonary embolism (PE), and no data on the effect of drotrecogin alfa (activated) (DAA) given in addition to therapeutic dose enoxaparin... CONCLUSIONS: In patients with acute submassive PE endogenous APC levels are low. DAA infusion enhances the inhibition of fibrin formation. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00191724.

Combination of activated protein C and topical negative pressure rapidly regenerates granulation tissue over exposed bone to heal recalcitrant orthopedic wounds. [2011]
Chronic wounds arising from orthopedic surgery present a major clinical challenge. Osteomyelitis may develop from polymicrobial infection, which can be unresponsive to treatment and lead to amputation...

more studies >>

Clinical Trials Related to Ceprotin (Protein C)

Ceprotin Treatment Registry [Recruiting]

more trials >>


Page last updated: 2014-04-08

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012